RWLK REWALK ROBOTICS LTD

RWLK INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving ReWalk Robotics Ltd. and a Lead Plaintiff Deadline of March 27, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased ReWalk Robotics Ltd. (NASDAQ:RWLK) securities pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014.

Click here to learn about the case: http://www.wongesq.com/pslra/rewalk-robotics. There is no cost or obligation to you.

According to the complaint, the Registration Statement and Prospectus issued in connection with the Initial Public Offering failed to disclose material information, including that ReWalk was unprepared and/or unable to comply with “special controls” requirements or to provide the U.S. Food and Drug Administration with a post-market surveillance study as required by the FDA for the Company to maintain ongoing sales of its products.

If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/rewalk-robotics.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
20/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

 PRESS RELEASE

Lifeward Expands International Distribution of its ReWalk® Personal Ro...

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable...

 PRESS RELEASE

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic...

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for  of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBORO...

 PRESS RELEASE

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Ap...

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received it...

 PRESS RELEASE

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Lifeward Ltd. Reports Third Quarter 2025 Financial Results Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch